High altitude may be synergistic with pulmonary hazards of appetite control medications fenfluramine and dexfenfluramine

Medical Hypotheses

Volumn 49, Issue 6, 1997, Pages 509-512

  Davis, W M ^a   Waters, I W ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXFENFLURAMINE; FENFLURAMINE;

ALTITUDE; APPETITE; DRUG TOXICITY; HUMAN; LUNG EDEMA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; TOXICOLOGY;

ANIMALIA;

EID: 0031442220     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(97)90070-0     Document Type: Article

References (25)

1. Abenhaim L, Monde Y, Brenot et al. Appetite suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335: 609-616.
2. Brenot F. Primary pulmonary hypertension: case series from France. Chest 1994; 195(suppl.): 33S-35S.
3. Manson J E. Faich G A. Pharmacotherapy for obesity - do the benefits outweigh the risks? N Engl J Med 1996; 335: 659-660.
4. Douglas J G, Munro J F, Kitchin A H, Muir A L. Proudfoot AT. Pulmonary hypertension and fenfluramine. Br Med J 1981; 283: 881-883.
5. McMurray J, Bloomfield P, Miller H C. Irreversible pulmonary hypertension after treatment with fenfluramine. Br Med J 1986; 292: 239-240.
6. Pouwels H M, Smeets I L, Cheriex E C, Wiuters E F. Pulmonary hypertension and fenfluramine. Eur Resp J 1990; 3: 606-607.
7. Gilbert D L, Franko B V, Ward J M, Woodard G, Courtney KD. Toxicological studies of fenfluramine. Toxicol Appl Pharmacol 1971;19: 705-711.
8. Hunsinger R N, Kibbe A H, Wilson M C. The effects of previous d-amphetamine treatment on the disposition and lethality of fenfluramine in the rat. Toxicol Appl Pharmacol 1985; 79: 236-245.
9. Hunsinger R N, Wright D. A characterization of the acute cardiopulmonary toxicity of fenfluramine in the rat. Pharmacol Res 1990; 22: 371-378.
10. Doogan D P. Pulmonary hypertension and fenfluramine. Br Med J 1982; 284: 1403.
11. Schenck C H, Mahowald M W. Potential hazard of serotonin syndrome associated with dexfenfluramine hydrochloride (Redux). J Am Med Assoc 1996; 276: 1220.
12. Anonymous. Wyeth Redux has quarter of antiobesity market after less than two months, Pondimin also growing. F-D-C Reports-The Pink Sheet, July 29, 1996: 15
13. Hitzig P. Combined serotonin and dopamine indirect agonists correct alcohol craving and alcohol-associated neuroses. J Subst Abuse Treatment 1994; 11: 489-490.
14. Sutton J R, Lassen N. Pathophysiology of acute mountain sickness and high altitude pulmonary oedema: an hypothesis. Bull Eur Physiopath Resp 1979; 15: 1045-1052.
15. Jerome E H, Sevringhaus J W. High-altitude pulmonary edema. N Engl J Med 1996; 334: 662-663.
16. Goetz A E, Kuebler W M, Peter K. High-altitude pulmonary edema. N Engl J Med 1996; 335: 205.
17. de'Clari. von Albertini M. High-altitude pulmonary edema. N Engl J Med 1996; 335: 207.
18. AMS (acute mountain sickness), a vascular occlusive disease. Med Hypotheses 1990; 31: 189-195.
19. West J B, Mathieu-Costello O. Stress failure of pulmonary capillaries: role in lung and heart disease. Lancet 1992; 340: 762-767.
20. Scherrer U, Vollenweider L, Delabaye A et al. Inhaled nitric oxide for high-altitude pulmonary edema. N Engl J Med 1996; 334: 624-629.
21. Atanassoff P G, Weiss B M, Schmid E R, Tornic M. Pulmonary hypertension and dexfenfluramine. Lancet 1992; 339: 436.
22. Maggiorini M, Bühler B, Walter M, Oelz O. Prevalence of acute mountain sickness in the Swiss Alps. Br Med J 1990; 301: 853-855.
23. Montgomery AB, Mills J, Luce JM. Incidence of acute mountain sickness at intermediate altitude. J Am Med Assoc 1989; 261: 732-736.
24. Honigman B, Theis M K, Koziol-McLain et al. Acute mountain sickness in a general tourist population at moderate altitudes. Ann Intern Med 1993; 118: 587-592.
25. Scoggin C H, Hyers T M, Reeves J T, Grovr R F. High-altitude pulmonary edema in the children and young adults of Leadville, Colorado. N Engl J Med 1977; 297: 1269-1272.